

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT6633712

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
NFINIUM VASCULAR TECHNOLOGIES, LLC	02/03/2021
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	VASCULAR DEVELOPMENT CORP, LLC
<b>Street Address:</b>	1556 WELLINGTON AVENUE
<b>City:</b>	GRAND JUNCTION
<b>State/Country:</b>	COLORADO
<b>Postal Code:</b>	81501
<b>PROPERTY NUMBERS Total: 14</b>	
<b>Property Type</b>	<b>Number</b>
Patent Number:	10335577
Application Number:	16407712
Application Number:	16724466
Patent Number:	9561094
Application Number:	15388271
Patent Number:	8740961
Application Number:	14231294
Application Number:	16018442
Patent Number:	7491210
Application Number:	14554348
Application Number:	14645830
Application Number:	16226832
Patent Number:	9498604
Patent Number:	9186487
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(650)493-6811
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	6508493012
<b>Email:</b>	jbereznak@wsgr.com, patentdocket@wsgr.com

<b>Correspondent Name:</b>	WILSON SONSINI GOODRICH & ROSATI
<b>Address Line 1:</b>	650 PAGE MILL ROAD
<b>Address Line 4:</b>	PALO ALTO, CALIFORNIA 94304-1050

<b>ATTORNEY DOCKET NUMBER:</b>	60778-700
--------------------------------	-----------

<b>NAME OF SUBMITTER:</b>	JOHN BEREZNAK
---------------------------	---------------

<b>SIGNATURE:</b>	/John Berezna/
-------------------	----------------

<b>DATE SIGNED:</b>	03/31/2021
---------------------	------------

**Total Attachments: 7**

source=Vascular Development Corp 60778-700 Portfolio Assignment (Nfinium to VDC)#page1.tif  
source=Vascular Development Corp 60778-700 Portfolio Assignment (Nfinium to VDC)#page2.tif  
source=Vascular Development Corp 60778-700 Portfolio Assignment (Nfinium to VDC)#page3.tif  
source=Vascular Development Corp 60778-700 Portfolio Assignment (Nfinium to VDC)#page4.tif  
source=Vascular Development Corp 60778-700 Portfolio Assignment (Nfinium to VDC)#page5.tif  
source=Vascular Development Corp 60778-700 Portfolio Assignment (Nfinium to VDC)#page6.tif  
source=Vascular Development Corp 60778-700 Portfolio Assignment (Nfinium to VDC)#page7.tif

## INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT

This Vascular Development Corp, LLC Intellectual Property Assignment Agreement (this "**Agreement**") is effective as of February 3, 2021 (the "**Effective Date**") by and between Vascular Development Corp, LLC, a Delaware limited liability company (the "**Company**"), Nfinium Vascular Technologies, LLC ("**Founding Member**").

### 1. Assignment

Founding Member hereby assigns to the Company exclusively throughout the world all Founding Member's right, title, and interest (choate or inchoate) in and to (a) all ideas, inventions, concepts, business plans, and related work associated with the business idea for which the Company has been formed, as outlined in **Exhibit A** hereto, (b) all work previously developed or produced in connection with the development of the Company's business, (c) all precursors, portions, and work in progress with respect thereto and all inventions, works of authorship, technology, information, know-how, techniques, concepts, ideas, materials, and tools relating thereto or to the development, support, or maintenance thereof, and (d) all copyrights, patent rights (including, without limitation, the patent rights and patent applications listed on **Exhibit A** hereto), trade secret rights, trademark rights, mask works rights, sui generis database rights, and all other intellectual and industrial property rights of any sort and all business, contract rights, causes of action, and goodwill in, incorporated or embodied in, used to develop, or related to any of the foregoing (collectively, the "**Intellectual Property**"). [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

### 2. Consideration [REDACTED]

As consideration for this Agreement the Company has or will [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED] shall be the only consideration required by the Founding Member in exchange for the Founding Member's assignment of the Intellectual Property to the Company in this Agreement taking into account [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

#### 4. Further Assurances; Moral Rights

(a)

(b) To the extent allowed by law, the Company and Founding Member acknowledge and agree that the assignment in Section 1 of this Agreement includes all rights of paternity, integrity, disclosure, and withdrawal and any other rights that may be known as or referred to as "moral rights," "artist's rights," "droit moral" or the like (collectively, "***Moral Rights***"). To the extent Founding Member retains any such Moral Rights under applicable law, Founding Member hereby ratifies and consents to, and provides all necessary ratifications and consents to, any action that may be taken with respect to such Moral Rights by or authorized by the Company; Founding Member agrees not to assert any Moral Rights with respect thereto. Founding Member will confirm any such ratifications, consents, and agreements from time to time as requested by the Company.

■

■

[REDACTED]

**7. Miscellaneous**

[REDACTED]

[REDACTED] If any provision of this Agreement shall be adjudged by any court of competent jurisdiction to be unenforceable or invalid, that provision shall be limited or eliminated to the minimum extent necessary so that this Agreement shall otherwise remain in full force and effect and enforceable. This Agreement shall be deemed to have been made in, and shall be construed pursuant to the laws of, the State of Colorado and the United States without regard to conflicts of laws provisions thereof. [REDACTED]

[REDACTED]


[REDACTED] Both parties agree that this Agreement is the complete and exclusive statement of the mutual understanding of the parties and supersedes and cancels all previous written and oral agreements and communications relating to the subject matter of this Agreement.

*[Signature page follows]*

IN WITNESS WHEREOF, the parties hereto have executed this Agreement effective as of the Effective Date.

**COMPANY:**

**VASCULAR DEVELOPMENT CORP, LLC,**  
a Delaware limited liability company

By: 


Name: James Draper  
Title: Managing Member

Address:

1556 Wellington Avenue  
Grand Junction, CO 81501

**FOUNDING MEMBER:**

**NFINIUM VASCULAR TECHNOLOGIES, LLC**

  
By: Richard Fulton (Jan 12, 2021 15:19 MST)

Name:  
Title:

Address:

1556 Wellington Avenue  
Grand Junction, CO 81501

**EXHIBIT A**

DESCRIPTION OF THE COMPANY'S BUSINESS FOR WHICH ALL RELATED INTELLECTUAL PROPERTY IS BEING ASSIGNED TO THE COMPANY PURSUANT TO THIS AGREEMENT:

The development and commercialization of technology and intellectual property for medical devices designed to remove thrombus and emboli throughout the vasculature of the body and to address health issues related to coronary artery disease, peripheral arterial disease, deep vein thrombosis, pulmonary embolism, carotid and neurological interventions, occlusion of vessels, delivery of medicaments to tumors and tissues and the diagnosis and treatment of other conditions.

The assignment of Intellectual Property herein covers all fields of use

[REDACTED]

LIST OF ASSIGNED TECHNOLOGY AND PATENTS:

Attached to the following page.

U.S. Patent No.	Continuation App. No.	Title	Priority Date	Issue Date	Expiry Date
10,335,577		Augmented delivery catheter and method	19-May-11	2-Jul-19	19-May-31
	16/407,712	Augmented delivery catheter and method			
	16/724,466	Augmented delivery catheter and method			
9,561,094		Devices and methods for treating venous diseases	25-Jul-11	7-Feb-17	25-Jul-31
	15/388,271	Devices and methods for treating venous diseases			
9,126,016		Augmented delivery catheter and method	19-May-11	8-Sep-15	19-May-31
	14/807,359	Augmented delivery catheter and method			
	16/724,466	Augmented delivery catheter and method			
8,740,961		Method for treating a target site in a vascular body channel	10-Jun-10	3-Jun-14	10-Jun-30
	14/231,294	Method for treating a target site in a vascular body channel			
	16/018,442	Method for treating a target site in a vascular body channel			
9,498,604		Medical device and method	15-Apr-04	22-Nov-16	15-Apr-24
	none				
9,186,487		Medical device and method	15-Apr-04	17-Nov-15	15-Apr-24
	14/201,371	Medical device and method			
7,491,210		Medical device and methods for use	9-Feb-99	17-Feb-09	9-Feb-19
	Original App. No.				
	14/554348	Low Radial Force Vascular Device and Method	6-Apr-14	pending	6-Apr-34

150704266.2



**EXHIBIT B**

[REDACTED]

[REDACTED]